Primary criterion to confirm CMA | Age (years) | CAP RAST to CM (kUA/l) | Symptoms evoked after most recent inadvertent CMP intake or DBPCFC to CMP |
Positive DBPCFC to CMP within 6 months of study enrolment | 0.7 | 70 | Pruritus, rash, urticaria/angioedema, rhinorrhoea |
0.9 | 12.2 | Pruritus, rash, urticaria/angioedema | |
1.1 | <0.35 | Pruritus, rash | |
1.3 | >100 | Pruritus, rash, urticaria/angioedema | |
1.4 | 9.9 | Pruritus, rash, urticaria/angioedema | |
1.6 | 15.7 | Urticaria/angioedema, sneezing/itching, laryngeal oedema | |
11.6 | 12.3 | Laryngeal oedema | |
Confirmatory CAP RAST to CM within 6 months of study enrolment | 0.6 | 7.16 | Pruritus, rash, urticaria/angioedema, wheezing |
0.8 | 17.1 | Pruritus, rash, urticaria/angioedema | |
1.5 | 22.4 | Pruritus, rash, urticaria/angioedema, sneezing/itching | |
1.6 | 34.5 | Pruritus, rash, vomiting | |
2.3 | >100 | * | |
2.4 | 61.8 | Pruritus, rash, urticaria/angioedema, vomiting | |
Adverse reaction to inadvertent CMP intake within 6 months and positive CAP RAST to CM within 12 months of study enrolment | 0.3 | 68.3 | Pruritus, rash, urticaria/angioedema, nasal congestion, sneezing/itching |
0.4 | 6.09 | Pruritus, rash, urticaria/angioedema, vomiting | |
0.5 | 4.59† | Pruritus, rash, urticaria/angioedema, nasal congestion, sneezing/itching | |
0.6 | 10.5 | Pruritus, rash, urticaria/angioedema, vomiting | |
0.6 | 9.01 | Pruritus, urticaria/angioedema, nasal congestion, sneezing/itching | |
0.6 | 57.3 | Pruritus, rash, urticaria/angioedema, nasal congestion, sneezing/itching, laryngeal oedema | |
0.7 | 7.46 | Pruritus, rash, urticaria/angioedema, nasal congestion, rhinorrhoea, sneezing/itching | |
0.7 | 9.05 | Pruritus, rash, urticaria/angioedema, rhinorrhoea, sneezing/itching | |
0.8 | 6.84 | Pruritus, rash, wheezing, vomiting | |
1.0 | 29.1 | Pruritus, rash, urticaria/angioedema | |
1.0 | 29.5 | Pruritus, rash, urticaria/angioedema | |
1.1 | 60.8 | Pruritus, rash, urticaria/angioedema, vomiting | |
1.3 | >100 | Urticaria/angioedema, rhinorrhoea, wheezing, diarrhoea, vomiting | |
1.4 | 23.9 | Pruritus, rash, urticaria/angioedema, vomiting | |
1.5 | 25.0 | Pruritus, rash, urticaria/angioedema, vomiting | |
1.6 | 30.5 | Pruritus, rash, urticaria/angioedema, rhinorrhoea, sneezing/itching | |
Anaphylaxis to CMP within 6 months and positive CAP RAST to CM within 12 months of study enrolment | 0.3 | 8.01 | Pruritus, rash, urticaria/angioedema, systemic anaphylaxis |
0.4 | 5 | Pruritus, rash, urticaria/angioedema, nasal congestion, rhinorrhoea, sneezing/itching, systemic anaphylaxis |
↵* Participant had a history suggestive of CMA beginning at 6 months of age and ongoing symptoms of atopic dermatitis at enrolment.
↵† Participant had sufficient evidence of CMA (exhibited multiple symptoms upon inadvertent CM intake within 3 months of enrolment) although CAP RAST to CM was slightly <5 kUA/l.
CM, cow's milk; CMA, cow's milk allergy; CMP, cow's milk protein; DBPCFC, double-blind placebo-controlled food challenge.